Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
Horizon, the official magazine for EU-funded research and innovation projects, has published an article about emerging treatments against diabetes. It includes an interview of the
Dear followers of the VANGUARD project, Since the VANGUARD website has been activated, we have received many messages from patients and their families enquiring about
The VANGUARD coordinator, Ekaterine Berishvili together with Charles-Henri Wassmer have recently published a new article in Current Diabetes Reports on the Immunomodulatory Properties of Amniotic